[18F]Fluorthanatrace PET in Ovarian Cancer: Comparison with [18F]FDG PET, Lesion Location, Tumor Grade, and Breast Cancer Gene Mutation Status
乳腺癌
核医学
癌症
卵巢癌
医学
内科学
作者
Joanna K. Weeks,Austin R. Pantel,Sarah B. Gitto,Fang Liu,Erin K. Schubert,Daniel A. Pryma,Michael D. Farwell,David A. Mankoff,Robert H. Mach,Fiona Simpkins,Lilie L. Lin
出处
期刊：The Journal of Nuclear Medicine [Society of Nuclear Medicine and Molecular Imaging] 日期：2024-12-05卷期号：: jnumed.124.267627-jnumed.124.267627
Poly(adenosine diphosphate-ribose) polymerase-1 (PARP1) inhibitors have improved ovarian cancer treatment outcomes. However, clinical response remains heterogeneous. Existing biomarkers, mainly breast cancer susceptibility genes 1 and 2 (
pluto
cdercder
昏睡的蟠桃
qiao
Oracle
bc
不倦
HEIKU
笨笨芯
iNk
平常的毛豆
小飞飞
研友_Y59785
HEAUBOOK
科研小民工
wy.he
归尘
pcr163
冰魂
善良的剑通
皖公网安备34019202002308
